Lnc-PHF3-3 aggravates the chemoresistance of osteosarcoma cells to doxorubicin via the miR-142-3p/HMGB1 axis
We conclude that Lnc-PHF3-3 contributes to doxorubicin resistance in OS by sequestering miR-142-3p and subsequently enhancing HMGB1 expression.
Authors
- Weisong Zhao (ORCID: https://orcid.org/0000-0002-5969-1956)
- Gangyang Wang (ORCID: https://orcid.org/0000-0003-1560-7684)
- Lingling Cao
- Mengkai Yang
- Jingyi Zhou (ORCID: https://orcid.org/0000-0002-6556-9447)
- Qi Li (ORCID: https://orcid.org/0000-0001-7070-7157)
- He Zhang (ORCID: https://orcid.org/0000-0002-2892-7647)
Institutions
- Shanghai Jiao Tong University (CN)
- Shanghai Chest Hospital (CN)
- Shanghai Cancer Institute (CN)
- Shanghai First People's Hospital (CN)
- Shanghai Sunshine Rehabilitation Center (CN)
- First Affiliated Hospital of Zhengzhou University (CN)
Publication Details
- Journal
- Translational Oncology
- Published
- 2025-02-18
- DOI
- https://doi.org/10.1016/j.tranon.2025.102328
- Citations
- 1
- Primary Topic
- Cancer-related molecular mechanisms research
- Type
- article
- Field-Weighted Citation Impact
- 0.94
Funders
- National Natural Science Foundation of China